GlobeNewswire Press

  1. Cambrex Completes Facility Expansion In North Carolina; Procures Analytical Lab Equipment 4/7/2020

    Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced it has completed an expansion of its biopharmaceutical analysis capabilities at the Durham, North Carolina site.

  2. Krystal Biotech Breaks Ground On Second Commercial Gene Therapy Manufacturing Facility 1/24/2020

    Krystal Biotech, Inc. (Nasdaq:KRYS), a gene therapy company developing medicines to treat rare diseases, announced today the ground breaking of the second commercial gene therapy facility in Findlay Township, Pennsylvania.

  3. Cure Pharmaceuticals To Increase Manufacturing Capacity; Add Blending And Packaging Technologies 10/9/2019

    CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®, one of the most advanced oral thin films on the market today.

  4. CDMO Avid Bioservices Completes Expansion Of Laboratories At California Campus 10/8/2019

    Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced the completion of the expansion of the company’s process development capabilities and laboratory space within its CDMO campus in Orange County, California.

  5. Dance Biopharm Rebrands, Now Aerami Therapeutics 9/25/2019

    Dance Biopharm, a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, today announced it is rebranding as Aerami Therapeutics and moving its headquarters to Durham, North Carolina.

  6. Mapi Pharma To Build New Sterile Injectable Production Plant In Jerusalem 7/15/2019

    Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company announced today that is has signed a long term lease agreement at the Har-Hotzvim Hi-Tech Park in Jerusalem for the establishment of a new sterile production plant for GA Depot injectable products.

  7. Aldevron To Build 14-Acre Gene Therapy Manufacturing Campus 6/3/2019

    Aldevron, a leader in the production of plasmid DNA, proteins, mRNA and antibodies; announced today expansion plans for a 14-acre campus at its headquarters in Fargo, N.D. Phase one construction will begin in August. Upon completion of the campus, the annual capacity will exceed $1 Billion of plasmid DNA, RNA, gene editing enzymes, and other biologics.

  8. Iovance Biotherapeutics Announces New Manufacturing Facility Plans For Cell Therapy Production 5/29/2019

    Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease agreement to build an approximately 136,000 square foot commercial-scale production facility in Philadelphia for commercial and clinical production of autologous TIL products, including its candidate lifileucel.

  9. Allogene Therapeutics Enters Lease To Build Manufacturing Facility To Develop And Commercialize Allogeneic CAR T (AlloCAR T™) Therapies 2/20/2019

    Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it has entered into a lease agreement to develop a 118,000 square foot cell therapy manufacturing facility in Newark, California.

  10. TRACON Pharmaceuticals Announces Positive Data From Ongoing Phase 1b/2 Trial Of TRC105 In Hepatocellular Carcinoma 1/22/2019

    TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that positive clinical data from its ongoing Phase 1b/2 study of TRC105 and Nexavar® (sorafenib) in patients with advanced hepatocellular carcinoma (HCC) were presented in a poster presentation at the ASCO 2019 Gastrointestinal Cancers Symposium in San Francisco on January 18, 2019.